Share This

Hot News

100%有效!這款艾滋病預防藥物取得驚人結果作者FX168 @ 2024-06-24T Back Hot News
Keyword:港股 國家隊
Concept:
十多年前,吉利德的藥物TRUVADA成為首個被批准用於未感染艾滋病毒的高危人群的PREP藥物。現在主流市場預防艾滋病預防主要是每日用藥,但制藥商現在正專注於開發長效藥物。如果正確使用PREP,通過性行為感染艾滋病毒的風險降低99%,通過注射毒品感染艾滋病毒的風險降低74%。然而,根據美國疾病控制與預防中心(CDCP)的數據,在美國,只有略高於三分之一的人服用了PREP。
當地時間6月20日,美國生物制藥公司吉利德在官網發布了公司自研新藥LENACAPAVIR一項Ⅲ期臨床試驗的中期結果。數據顯示,LENACAPAVIR在女性艾滋病毒暴露前預防(PREP)的有效率達到100%,這一數據優於吉利德現有的口服抗HIV藥物TRUVADA(恩曲他濱替諾福韋片)。LENACAPAVIR是一款FIRST-IN-CLASS(全球首創)的長效HIV衣殼抑制劑,每半年一針,通過皮下注射。
(來那卡帕韋)在預防年輕女性艾滋病感染試驗中顯示出100%的有效率,證明其作為預防艾滋病感染重要新工具的潛力。

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.